Seyed Ali Ghahari
Seyed Ali Ghahari has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
- Morteza Maleki
Winship Cancer Institute, Emory University, USA
2 shared publications
Latest Publications
- Open Access
- 3 September 2025
- Published by MDPI AG in Preprints.org
Symmetrical Catalysis and C-H Activation in Unsaturated Amides and Esters of Osmium: Applications in Pharmaceuticals Drug Synthesis
We report the selective activation and transformation of unsaturated amides and esters at multinuclear osmium carbonyl clusters and clarify how these symmetry-enabled, cooperative reactions inform pharmaceutical synthesis. Treatment of the activated triosmium complex Os3(CO)10(NCCH3)2 with N,N-dimethylacrylamide (DMA) or methylacrylate (MA) furnishes eight structurally characterized products spanning Os2, Os3, Os4, Os5, and Os6 nuclearities. Single-crystal X-ray diffraction, IR, NMR, and MS data establish (i) β-C–H activation of the alkene unit to give bridg- ing μ-alkenyl/μ-hydride motifs, (ii) substrate–substrate coupling on the cluster to form a chelated DMA–DMA dimer, and (iii) carbonylation/decarbonylation events that reorganize Os–Os connectivity. The key intermediate HOs3(CO)10(μ-acryloyl) maps a stepwise sequence in which two or more metal centers share bond-making/bond-breaking—an intrinsic “symmetrical catalysis" element arising from the defined Os–Os edges. Solvent governs pathway selection: noncoordinating, higher-boiling media (e.g., heptane) favor direct C–H activation and dimerization, whereas CH2Cl2 enables gentler transformations that preserve cluster integrity and access higher nuclearities. Although the ransformations are stoichiometric, they recapitulate catalytic elementary steps central to late-stage functionalization and feedstock upgrading—concerted C–H cleavage, migratory insertion of CO, and controlled C–C coupling—and thus offer design rules for bimetallic/cluster catalysts targeting drug-like motifs (enamides, dienamides, and 1,4-dicarbonyl frameworks). By linking structure, mechanism, and chemoselectivity across a family of symmetric Os clusters, this work provides a mechanistic platform for translating cooperative multimetal activation into future catalytic processes relevant to API synthesis and process intensification.
- 3 September 2025
- Published by MDPI AG in Preprints.org
Open AccessSymmetrical Catalysis and C-H Activation in Unsaturated Amides and Esters of Osmium: Applications in Pharmaceuticals Drug Synthesis
We report the selective activation and transformation of unsaturated amides and esters at multinuclear osmium carbonyl clusters and clarify how these symmetry-enabled, cooperative reactions inform pharmaceutical synthesis. Treatment of the activated triosmium complex Os3(CO)10(NCCH3)2 with N,N-dimethylacrylamide (DMA) or methylacrylate (MA) furnishes eight structurally characterized products spanning Os2, Os3, Os4, Os5, and Os6 nuclearities. Single-crystal X-ray diffraction, IR, NMR, and MS data establish (i) β-C–H activation of the alkene unit to give bridg- ing μ-alkenyl/μ-hydride motifs, (ii) substrate–substrate coupling on the cluster to form a chelated DMA–DMA dimer, and (iii) carbonylation/decarbonylation events that reorganize Os–Os connectivity. The key intermediate HOs3(CO)10(μ-acryloyl) maps a stepwise sequence in which two or more metal centers share bond-making/bond-breaking—an intrinsic “symmetrical catalysis" element arising from the defined Os–Os edges. Solvent governs pathway selection: noncoordinating, higher-boiling media (e.g., heptane) favor direct C–H activation and dimerization, whereas CH2Cl2 enables gentler transformations that preserve cluster integrity and access higher nuclearities. Although the ransformations are stoichiometric, they recapitulate catalytic elementary steps central to late-stage functionalization and feedstock upgrading—concerted C–H cleavage, migratory insertion of CO, and controlled C–C coupling—and thus offer design rules for bimetallic/cluster catalysts targeting drug-like motifs (enamides, dienamides, and 1,4-dicarbonyl frameworks). By linking structure, mechanism, and chemoselectivity across a family of symmetric Os clusters, this work provides a mechanistic platform for translating cooperative multimetal activation into future catalytic processes relevant to API synthesis and process intensification.
- Open Access
- 1 September 2025
- Published by MDPI AG in Preprints.org
Multimodal Generative AI in Diagnostics: Bridging Medical Imaging and Clinical Reasoning
Multimodal generative artificial intelligence (AI) has emerged as a transformative technology in clinical diagnostics, integrating diverse data sources—medical imaging, genomic profiles, clinical narratives, and electronic health records—to significantly enhance diagnostic accuracy, clinical decision-making, and personalized patient care. This review systematically explores the landscape of multimodal AI across key medical specialties, including radiology, pathology, dermatology, ophthalmology, neurology, and oncology, highlighting recent methodological advancements, performance evaluations, and practical clinical implementations. Technical strategies such as tool-use, grafting, and unified multimodal architectures are critically assessed, identifying their strengths and limitations concerning clinical applicability, interpretability, and computational efficiency. Synthetic multimodal data generation methodologies—Generative Adversarial Networks (GANs), Variational Autoencoders (VAEs), diffusion models, and large language models (LLMs)—are evaluated for addressing data scarcity in rare disease research, enhancing international collaboration, and mitigating privacy concerns. Additionally, this review addresses pivotal ethical, regulatory, and liability challenges, emphasizing fairness, transparency, and accountability in AI-driven clinical diagnostics. Strategic priorities for future research are identified, including rigorous prospective clinical validation, development of standardized multimodal datasets, enhanced model interpretability, and robust regulatory frameworks. Ultimately, realizing the transformative potential of multimodal generative AI in clinical practice will require interdisciplinary collaboration among clinicians, researchers, ethicists, regulators, and patient advocacy groups, ensuring these powerful tools effectively augment human expertise, improve healthcare delivery, and advance precision medicine.
- 1 September 2025
- Published by MDPI AG in Preprints.org
Open AccessMultimodal Generative AI in Diagnostics: Bridging Medical Imaging and Clinical Reasoning
Multimodal generative artificial intelligence (AI) has emerged as a transformative technology in clinical diagnostics, integrating diverse data sources—medical imaging, genomic profiles, clinical narratives, and electronic health records—to significantly enhance diagnostic accuracy, clinical decision-making, and personalized patient care. This review systematically explores the landscape of multimodal AI across key medical specialties, including radiology, pathology, dermatology, ophthalmology, neurology, and oncology, highlighting recent methodological advancements, performance evaluations, and practical clinical implementations. Technical strategies such as tool-use, grafting, and unified multimodal architectures are critically assessed, identifying their strengths and limitations concerning clinical applicability, interpretability, and computational efficiency. Synthetic multimodal data generation methodologies—Generative Adversarial Networks (GANs), Variational Autoencoders (VAEs), diffusion models, and large language models (LLMs)—are evaluated for addressing data scarcity in rare disease research, enhancing international collaboration, and mitigating privacy concerns. Additionally, this review addresses pivotal ethical, regulatory, and liability challenges, emphasizing fairness, transparency, and accountability in AI-driven clinical diagnostics. Strategic priorities for future research are identified, including rigorous prospective clinical validation, development of standardized multimodal datasets, enhanced model interpretability, and robust regulatory frameworks. Ultimately, realizing the transformative potential of multimodal generative AI in clinical practice will require interdisciplinary collaboration among clinicians, researchers, ethicists, regulators, and patient advocacy groups, ensuring these powerful tools effectively augment human expertise, improve healthcare delivery, and advance precision medicine.